Towards Healthcare Research & Consulting

Carcinoembryonic Antigen (CEA) Market Size, Share, Forecast (2026-2035), CEA Assays, Kits and Analyzers for Colorectal, Lung, Breast and Gastrointestinal Cancer Monitoring

The carcinoembryonic antigen (CEA) market is estimated at USD 3.30 billion in 2026 and is projected to reach USD 5.53 billion by 2035, expanding at a CAGR of 5.90% from 2026 to 2035. The market was valued at USD 3.12 billion in 2025, the base year. The market includes CEA tests, including reagents and kits, immunoassay analyzers, and point-of-care testing solutions. These products use chemiluminescence, ELISA, electrochemiluminescence, and other immunoassay methods to monitor treatment response and cancer recurrence in colorectal, lung, breast, pancreatic, and other gastrointestinal cancers. Key end users include hospitals, diagnostic laboratories, cancer centers, and research institutes. Reagents & Kits accounted for the largest product share in 2025, at 66.00%, because every CEA test uses consumable reagents on installed analyzers. Asia Pacific accounted for 38.00% of revenue in 2025, supported by very large tumor marker volumes in China and Japan. 

Last updated 18 November 2026   |   Primary source: Towards Healthcare   |   Report: 7197   |   Derived values are labelled
USD 3.30 Bn
Revenue, 2026
USD 5.53 Bn
Forecast, 2035
5.90%
CAGR, 2026-2035
Global
Report Coverage

Key Takeaways

Carcinoembryonic Antigen Market Snapshot, Comparison and Top Companies

Market Size & Growth Outlook

  • Market size in 2025: USD 3.12 billion
  • Estimated market size in 2026: USD 3.30 billion
  • Projected market size by 2035: USD 5.53 billion
  • CAGR (2026-2035): 5.90%

Regional Market Spotlight

  • Asia Pacific led the market with a 38.00% share in 2025 and is projected to be the fastest-growing region, at a CAGR of 6.62% from 2026 to 2035.
  • North America accounted for 29.00% of the market in 2025.
  • Europe accounted for 25.00% of the market in 2025.

Segmental Spotlight

  • By product, Reagents & Kits held the largest share at 66.00% in 2025.
  • By technology, Chemiluminescence (CLIA) dominated with a 52.00% market share in 2025.
  • By application, Colorectal Cancer represented 46.00% of the market in 2025.
  • By end user, Hospitals contributed 48.00% of the market in 2025.

The carcinoembryonic antigen (CEA) market is projected to grow from USD 3.12 billion in 2025 to USD 5.53 billion by 2035 because CEA is a low-cost, guideline-backed tumor marker run in high volumes for colorectal and other cancers. Cancer survivorship, rising incidence, Asian check-up panels, and automated immunoassays support steady growth, lifting the market to USD 4.16 billion by 2030 and sustaining a CAGR of 5.90% during the forecast period. CEA monitoring increasingly pairs with next-generation sequencing and precision medicine in colorectal cancer care.

Carcinoembryonic Antigen Market Size is USD 3.30 Billion in 2026.

Analyst View: We built the estimate from CEA test volumes and average reagent prices by region, plus analyzer share, cross-checked against tumor marker revenues of leading suppliers. Our value sits above published comparable estimates because it includes analyzer value.

  • Increasing use of CEA alongside other tumor biomarkers is improving cancer monitoring and supporting more comprehensive diagnostic assessments.
  • Expansion of domestic diagnostic reagent and test kit production in China is improving supply availability and supporting regional market growth.
  • Growing adoption of automated chemiluminescence immunoassay systems is improving testing efficiency, throughput, and accuracy in clinical laboratories.
  • Combining CEA testing with circulating tumor DNA (ctDNA) analysis is strengthening post-treatment surveillance and supporting earlier detection of cancer recurrence.
  • Increasing demand for rapid diagnostic solutions is encouraging the development of point-of-care CEA tests that enable faster clinical decision-making.
  • Efforts to standardize CEA testing methods and calibration practices are improving result consistency and comparability across laboratories and diagnostic platforms.

Drivers, Restraints and Opportunities

Market Drivers - Impact & CAGR Contribution (2026-2035)

Driver Impact ≈ CAGR Contribution Time Horizon Key Regions
Colorectal cancer survivors need monitoring High +2.30 pp Short to long term Global, strongest in Asia Pacific
Cancer incidence rises Medium +1.94 pp Medium to long term Global, fastest uptake in Asia Pacific
Health check-up panels in Asia Medium +1.66 pp Short to medium term Global
Automated immunoassays Low +1.30 pp Long term Developed and emerging markets

Note: Contributions are indicative estimates of each factor's effect on annual growth.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Taken together, these drivers add about 7.20 percentage points to the annual growth of the carcinoembryonic antigen (CEA) market, with colorectal cancer survivors need monitoring having the largest effect. Their influence is strongest in Asia Pacific, while uptake grows fastest in Asia Pacific.

Market Restraints - Impact & Negative CAGR Contribution (2026-2035)

Restraint Impact ≈ Negative CAGR Contribution Time Horizon Key Regions
Low specificity for screening High -0.58 pp Short to medium term Global
Competition from ctDNA tests High -0.43 pp Medium term Price-sensitive and emerging markets
Price pressure from volume-based procurement Medium -0.29 pp Short term Asia Pacific and other mature markets

Note: Contributions are indicative estimates of each factor's effect on annual growth.

Sources: Expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.

These restraints are expected to reduce annual growth of the carcinoembryonic antigen (CEA) market by about 1.30 percentage points, led by low specificity for screening. Their effect eases over the forecast period as suppliers, buyers and regulators adapt, leaving a net CAGR of 5.90% from 2026 to 2035.

Market Opportunity

Expanding diagnostic infrastructure and rising cancer awareness across Asia and emerging economies are creating opportunities for CEA testing providers. Combining CEA with ctDNA offers potential for more comprehensive cancer recurrence monitoring. Additionally, growing demand for point-of-care testing and investments in laboratory automation are supporting opportunities for rapid diagnostic solutions, advanced immunoassay analyzers and compatible testing kits.

Market Segmentation: 2025 Share and Value

Carcinoembryonic Antigen (CEA) Market by Product 2025 Share

Carcinoembryonic Antigen Market, By Product, Segment Dominates by 66% in 2025.

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Reagents & Kits: Holding a 66.00% share of the carcinoembryonic antigen (CEA) market in 2025, this segment is projected to expand at a CAGR of 5.60% during the forecast period. Reagents and kits dominate because every CEA test requires consumable reagents compatible with installed analyzers. Growth is expected to remain broadly in line with the overall market over the forecast period.

Analyzers: Hospitals, diagnostic laboratories, and reference centers use immunoassay analyzers to perform routine and high-volume CEA testing. Growth is expected to remain broadly in line with the overall market.

Point-of-Care Tests & Others: Growing adoption of rapid testing solutions in smaller hospitals, clinics, and decentralized healthcare facilities is supporting demand. Growth is expected to exceed the overall market over the forecast period.

Segment Outlook: Reagents & Kits remains the largest product segment through 2035, holding about 64.20% of the market in 2035, while Point-of-Care Tests & Others records the highest CAGR of 7.50% from 2026 to 2035. Although Point-of-Care Tests & Others starts from the smallest base, its faster growth shows how demand is shifting within the carcinoembryonic antigen (CEA) market.

Carcinoembryonic Antigen (CEA) Market by Technology 2025 Share

Carcinoembryonic Antigen Market, By Technology, Segment Dominates by 52% in 2025.

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Chemiluminescence (CLIA): Holding a 52.00% share of the carcinoembryonic antigen (CEA) market in 2025, this segment is projected to expand at a CAGR of 6.09% during the forecast period. CLIA leads due to the widespread adoption of automated platforms that support high-volume tumor marker testing in hospitals and diagnostic laboratories. Growth is expected to remain broadly in line with the overall market over the forecast period.

Electrochemiluminescence (ECLIA): Technology is widely used in high-throughput analyzers, offering reliable and efficient processing of routine CEA tests. Growth is expected to remain broadly in line with the overall market.

ELISA: Remains relevant in smaller diagnostic laboratories and research settings due to its established protocols and relatively accessible testing infrastructure. Growth is expected to remain broadly in line with the overall market.

Others: It includes alternative testing methods such as lateral flow assays, which support rapid and decentralized CEA testing. Growth is expected to remain broadly in line with the overall market.

Segment Outlook: Chemiluminescence (CLIA) remains the largest technology segment through 2035, holding about 52.98% of the market in 2035, and also records the highest CAGR of 6.09% during the forecast period, strengthening its lead in the carcinoembryonic antigen (CEA) market.

Carcinoembryonic Antigen (CEA) Market by Application 2025 Share

Carcinoembryonic Antigen Market, By Application, Segment Dominates by 46% in 2025.

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Towards Healthcare database, and Towards Healthcare analysts.

Colorectal Cancer: Holding a 46.00% share of the carcinoembryonic antigen (CEA) market in 2025, this segment is projected to expand at a CAGR of 5.50% from 2026 to 2035. Colorectal cancer represents the leading application due to the established use of CEA for monitoring treatment response and detecting recurrence following surgery. Growth is expected to remain slower than the overall market over the forecast period.

Lung Cancer: CEA testing supports lung cancer monitoring and is often used alongside other tumor markers to provide additional clinical information. Growth is expected to remain broadly in line with the overall market.

Breast Cancer: CEA testing supports the monitoring of advanced and metastatic breast cancer, particularly in assessing treatment response and disease progression. Growth is expected to remain broadly in line with the overall market.

Pancreatic & Gastric Cancer: Increasing adoption of tumor marker testing, expanding diagnostic infrastructure, and rising cancer awareness across Asia are supporting demand for CEA testing in pancreatic and gastric cancer management. Growth is expected to exceed the overall market over the forecast period.

Others: It includes CEA testing applications across other gastrointestinal and non-gastrointestinal cancers, supporting treatment monitoring and disease surveillance. Growth is expected to remain broadly in line with the overall market.

Segment Outlook: Colorectal Cancer remains the largest application segment through 2035, holding about 44.30% of the market in 2035, while Pancreatic & Gastric Cancer records the highest CAGR of 7.10% from 2026 to 2035. Others hold the smallest share today and serve more specialised needs within the carcinoembryonic antigen (CEA) market.

Carcinoembryonic Antigen (CEA) Market by End User 2025 Share

Carcinoembryonic Antigen Market, By End User, Segment Dominates by 48% in 2025.

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Hospitals: Holding a 48.00% share of the carcinoembryonic antigen (CEA) market in 2025, this segment is projected to expand at a CAGR of 5.50% during the forecast period. Hospitals lead due to their central role in cancer diagnosis, treatment, and post-treatment monitoring, which drives routine CEA testing among oncology patients. Growth is expected to remain slower than the overall market over the forecast period.

Diagnostic Laboratories: Support demand through routine tumor marker testing, specialized CEA assays, and multi-marker panels for cancer monitoring. Growth is expected to remain broadly in line with the overall market.

Cancer Centres & Research: Increasing oncology research activities, clinical trials and specialized cancer monitoring programmes are driving demand for CEA testing across cancer centers and research institutes. Growth is expected to exceed the overall market over the forecast period.

Segment Outlook: Hospitals remains the largest end user segment through 2035, holding about 46.29% of the market in 2035, while Cancer Centres & Research records the highest CAGR of 6.90% from 2026 to 2035. Although Cancer Centres & Research starts from the smallest base, its faster growth shows how demand is shifting within the carcinoembryonic antigen (CEA) market.

Analyst View: Segment shares were allocated from demand, product portfolios, and pricing in each category. Reagents & Kits, Chemiluminescence (CLIA), Colorectal Cancer and Hospitals lead their categories because they meet the core needs of today's buyers. We expect Point-of-Care Tests & Others, Pancreatic & Gastric Cancer and Cancer Centres & Research to gain share as newer technologies, users and applications grow faster.

Regional Analysis

Carcinoembryonic Antigen Market Shares for North America, Europe, Asia Pacific, Latin America and Middle East and Africa, 2025 (%).

Carcinoembryonic Antigen (CEA) Market by Region 2025 Share

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Towards Healthcare database, and Towards Healthcare analysts.

Asia Pacific: Holding a 38.00% share of the carcinoembryonic antigen (CEA) market in 2025, Asia Pacific is set to grow at a CAGR of 6.63% from 2026 to 2035. The region leads the global market and records the fastest growth, supported by high tumor marker testing volumes in China and Japan and the growing inclusion of CEA tests in routine health check-up panels. Its growth is expected to exceed the overall market average.

North America: Established colorectal cancer surveillance practices, widespread access to diagnostic laboratories, and high volumes of routine oncology testing support regional demand. Growth is expected to remain slower than the overall market.

Europe: Established healthcare infrastructure and guideline-based CEA monitoring practices support the adoption of tumor marker testing across hospitals and diagnostic laboratories. Growth is expected to remain slower than the overall market.

Latin America: Growing oncology testing volumes, improving diagnostic infrastructure, and expanding access to cancer care are supporting regional demand for CEA testing. Growth is expected to remain slower than the overall market.

Middle East & Africa: Investments in cancer care facilities, expanding diagnostic capabilities, and improving access to oncology services are supporting the adoption of CEA testing. Growth is expected to remain slower than the overall market.

Analyst View: Regional shares were built from demand, installed base, spending, and supplier presence in each region. Asia Pacific leads because of its mature demand base and strong suppliers. We assign Asia Pacific the highest growth premium because investment, adoption and capacity are expanding fastest there.

Competitive Landscape

Carcinoembryonic Antigen Market Companies are Roche Diagnostics, Abbott, Siemens Healthineers, Beckman Coulter (Danaher), Mindray, Snibe, Fujirebio, QuidelOrtho, Tosoh, Autobio Diagnostics

Top 10 Companies in the Carcinoembryonic Antigen (CEA) Market, 2025

Rank Company Name Key Products / Business Headquarters
1 Roche Diagnostics Elecsys CEA on cobas e analyzers Switzerland
2 Abbott Alinity i and ARCHITECT CEA United States
3 Siemens Healthineers Atellica and ADVIA Centaur CEA Germany
4 Beckman Coulter (Danaher) Access CEA United States
5 Mindray CL-series CLIA tumour markers China
6 Snibe MAGLUMI CLIA tumour markers China
7 Fujirebio Lumipulse tumour markers Japan
8 QuidelOrtho VITROS CEA United States
9 Tosoh AIA CEA assays Japan
10 Autobio Diagnostics CLIA tumour marker assays China

Note: Company shares are 2025 estimates.

Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Roche Diagnostics led the carcinoembryonic antigen (CEA) market with an impressive share of 2025 revenue, followed by Abbott and Siemens Healthineers. Roche Diagnostics leads with elecsys CEA on cobas e analyzers, Abbott competes with alinity i and ARCHITECT CEA, and Siemens Healthineers offers atellica and ADVIA Centaur CEA. Beckman Coulter (Danaher), Mindray, Snibe, Fujirebio, QuidelOrtho, Tosoh and Autobio Diagnostics compete through access CEA, CL-series CLIA tumor markers, MAGLUMI CLIA tumor markers, lumipulse tumour markers, VITROS CEA, AIA CEA assays and CLIA tumour marker assays. The carcinoembryonic antigen (CEA) market is concentrated among large immunoassay suppliers, and competition centres on analyzer installed base, assay standardization, throughput, menu breadth, local manufacturing and price per test.

Company Snapshots

Roche Diagnostics: Headquartered in Switzerland and operating as part of F. Hoffmann-La Roche Ltd, Roche Diagnostics maintains a strong presence in the global carcinoembryonic antigen (CEA) testing industry. Its portfolio features Elecsys CEA assays compatible with cobas e analyzers. Towards Healthcare positions the company as a Leader in its Companies Quadrant.

Abbott: Headquartered in the United States, Abbott offers Alinity i and ARCHITECT CEA testing solutions for clinical diagnostics. Its established immunoassay platforms support routine tumor marker testing across hospitals and diagnostic laboratories. It holds a Leader position in the Towards Healthcare Companies Quadrant.

Siemens Healthineers: Based in Germany, Siemens Healthineers offers Atellica and ADVIA Centaur CEA assays, supporting automated tumor marker testing and laboratory workflows. Towards Healthcare classifies the company as a Leader in its Companies Quadrant.

Beckman Coulter (Danaher): A U.S.-based diagnostics company under Danaher, Beckman Coulter offers Access CEA assays for routine tumor marker testing across clinical laboratories. The company is positioned as a Leader in the Towards Healthcare Companies Quadrant.

Mindray: Headquartered in China and operating as part of Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Mindray offers CL-series chemiluminescence immunoassay (CLIA) tumor marker tests. Towards Healthcare identifies the company as a Leader in its Companies Quadrant.

Snibe: Based in China, Snibe, part of Shenzhen New Industries Biomedical Engineering Co., Ltd., specializes in MAGLUMI CLIA-based tumor marker testing solutions. It is recognized as a Leader in the Towards Healthcare Companies Quadrant.

Fujirebio: A Japanese diagnostics company operating under H.U. Group Holdings, Inc., Fujirebio offers Lumipulse platform-based tumor marker testing solutions for clinical diagnostics. Towards Healthcare positions the company as an Innovator in its Companies Quadrant.

QuidelOrtho: Headquartered in the United States, QuidelOrtho provides VITROS CEA assays that support automated tumor marker testing in clinical laboratory settings. The company is classified as an Innovator in the Towards Healthcare Companies Quadrant.

Tosoh: With headquarters in Japan, Tosoh offers AIA CEA assays for clinical laboratories requiring immunoassay-based tumor marker testing. Towards Healthcare identifies the company as an Innovator in its Companies Quadrant.

Autobio Diagnostics: Based in China, Autobio Diagnostics focuses on CLIA-based tumor marker assays for oncology diagnostics. The company occupies an Innovator position in the Towards Healthcare Companies Quadrant.

Companies Ecosystem

The carcinoembryonic antigen (CEA) ecosystem links antibody & reagent suppliers, assay & analyzer makers, distributors, users and regulators & guidelines, with each stage adding value before products reach end users.

Ecosystem Stage Role in the Market Key Companies
Antibody & Reagent Suppliers Supply antibodies and calibrators Reagent makers
Assay & Analyzer Makers Make CEA tests and platforms Roche, Abbott, Siemens Healthineers, Mindray, Snibe
Distributors Supply labs Lab distributors
Users Run tests Hospitals, labs, cancer centres
Regulators & Guidelines Clear tests and set use FDA, NMPA, ASCO, NCCN

Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Antibody & Reagent Suppliers: Supply antibodies and calibrators. Key participants include Reagent makers.

Assay & Analyzer Makers: Make CEA tests and platforms. Key participants include Roche, Abbott, Siemens Healthineers, Mindray, Snibe.

Distributors: Supply labs. Key participants include Lab distributors.

Users: Run tests. Key participants include Hospitals, labs, cancer centers.

Regulators & Guidelines: Clear tests and set use. Key participants include FDA, NMPA, ASCO, NCCN.

Value in the carcinoembryonic antigen (CEA) market flows from upstream material and technology suppliers to manufacturers and service providers, then through distribution partners to end users. Companies that integrate several stages or build long-term relationships with end users capture a larger share of this value.

Towards Healthcare Companies Quadrant

The Towards Healthcare Companies Quadrant positions key participants in the carcinoembryonic antigen (CEA) market by market strength, reflecting revenue scale, market share and geographic reach, and by innovation and growth strategy, reflecting product portfolio breadth, R&D intensity and partnerships. Positions reflect each company's estimated 2025 share of the carcinoembryonic antigen (CEA) market and our assessment of its product innovation, portfolio breadth and partnerships.

Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Leaders: Roche Diagnostics, Abbott, Siemens Healthineers, Beckman Coulter (Danaher), Mindray and Snibe combine high market share with broad portfolios and strong innovation.

Innovators: Fujirebio, QuidelOrtho, Tosoh and Autobio Diagnostics bring newer technologies and specialized products.

Recent Developments

  • November 2025: Roche Diagnostics launched locally made Elecsys PGI and PGII gastric cancer risk tests in China, produced at its Suzhou site and run on the same cobas e analyzers used for its Elecsys tumour marker menu, including CEA.

Market Segments

By Product

  • Reagents & Kits
  • Analyzers
  • Point-of-Care Tests & Others

By Technology

  • Chemiluminescence (CLIA)
  • Electrochemiluminescence (ECLIA)
  • ELISA
  • Others

By Application

  • Colorectal Cancer
  • Lung Cancer
  • Breast Cancer
  • Pancreatic & Gastric Cancer
  • Others

By End User

  • Hospitals
  • Diagnostic Laboratories
  • Cancer Centres & Research

By Region

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., France, Italy, Spain, Rest of Europe)
  • Asia Pacific (China, Japan, India, South Korea, Taiwan, Rest of Asia Pacific)
  • Latin America (Brazil, Argentina, Rest of Latin America)
  • Middle East & Africa (GCC, South Africa, Rest of MEA)

Research Methodology

The carcinoembryonic antigen (CEA) market was defined as carcinoembryonic antigen tests, including CEA reagents and kits, immunoassay analyzers and point-of-care tests, based on chemiluminescence, ELISA, electrochemiluminescence and other immunoassay methods, used to monitor treatment response and recurrence in colorectal, lung, breast, pancreatic and other gastrointestinal cancers by hospitals, diagnostic laboratories, cancer centers and research institutes. The 2025 base year was built bottom-up from demand volumes and average prices by product, technology, application and end user and region, and checked top-down against the market-specific revenues of leading companies and published estimates.

Segment, regional and company values were allocated from product, technology, application, and end user and region demand. Key estimates were verified by cross-checking company disclosures, regulatory and industry data and published third-party estimates, and inputs that could not be reconciled were excluded. All segment, regional and company figures were reconciled to the same 2025 base year, and the 2026-2035 forecast, which applies a constant CAGR from the 2025 base, was recalculated and validated.

Analyst View: The carcinoembryonic antigen (CEA) market is set for steady expansion as cancer survivorship and related demand keep growing. Our estimate links value to underlying demand, installed base and pricing, so the forecast follows real adoption rather than headline hype. The main upside comes from Asian testing growth and CEA plus ctDNA monitoring, while the main risks are low specificity and price pressure.

References

Meet the Team

Payal Rabde

Payal Rabde

Principal Consultant

Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.

Learn more about Payal Rabde
Aditi Shivarkar

Aditi Shivarkar LinkedIn

Reviewed By

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar